Kåre Andersson Gotschalck

Kåre Andersson Gotschalck

Auto-generated profile, based on publicly available information

Kåre Andersson Gotschalck

Department of Clinical Medicine Aarhus University Aarhus Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
TRThomas Reinert
Thomas Reinert
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
ECEmil Christensen
Emil Christensen
SSShruti Sharma
Shruti Sharma
RSRaheleh Salari
Raheleh Salari
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
With 1.3 million newly diagnosed cases each year, colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths.1 Despite improved surgery, implementation of screening, and advances in treatment regimens, the 5-year mortality rate for patients with CRC remains high at approximately 40%, thereby representing a significant global health burden.2,3

1 October 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
NTNoelia Tarazona
Noelia Tarazona
AFAmanda Frydendahl
Amanda Frydendahl
TRThomas Reinert
Thomas Reinert
FGFrancisco Gimeno-Valiente
Francisco Gimeno-Valiente
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. Experimental Design: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. Results: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. Conclusions: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438

14 November 2019 in Clinical Epigenetics
Verified
Journal Article
Open access
SJSarah Østrup Jensen
Sarah Østrup Jensen
NØNadia Øgaard
Nadia Øgaard
MØMai-Britt Worm Ørntoft
Mai-Britt Worm Ørntoft
MRMads Heilskov Rasmussen
Mads Heilskov Rasmussen
JBJesper Bertram Bramsen
Jesper Bertram Bramsen
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Background: Early detection plays an essential role to reduce colorectal cancer (CRC) mortality. While current screening methods suffer from poor compliance, liquid biopsy-based strategies for cancer detection is rapidly gaining promise. Here, we describe the development of TriMeth, a minimal-invasive blood-based test for detection of early-stage colorectal cancer. The test is based on assessment of three tumour-specific DNA methylation markers in circulating cell-free DNA. Results: A thorough multi-step biomarker discovery study based on DNA methylation profiles of more than 5000 tumours and blood cell populations identified CRC-specific DNA methylation markers. The DNA methylation patterns of biomarker candidates were validated by bisulfite sequencing and methylation-specific droplet digital PCR in CRC tumour tissue and peripheral blood leucocytes. The three best performing markers were first applied to plasma from 113 primarily early-stage CRC patients and 87 age- and gender-matched colonoscopy-verified controls. Based on this, the test scoring algorithm was locked, and then TriMeth was validated in an independent cohort comprising 143 CRC patients and 91 controls. Three DNA methylation markers, C9orf50, KCNQ5, and CLIP4, were identified, each capable of discriminating plasma from colorectal cancer patients and healthy individuals (areas under the curve 0.86, 0.91, and 0.88). When combined in the TriMeth test, an average sensitivity of 85% (218/256) was observed (stage I: 80% (33/41), stage II: 85% (121/143), stage III: 89% (49/55), and stage IV: 88% (15/17)) at 99% (176/178) specificity in two independent plasma cohorts. Conclusion: TriMeth enables detection of early-stage colorectal cancer with high sensitivity and specificity. The reported results underline the potential utility of DNA methylation-based detection of circulating tumour DNA in the clinical management of colorectal cancer.

24 May 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KSKåre G. Sunesen
Kåre G. Sunesen
MNMette Nørgaard
Mette Nørgaard
OTOle Thorlacius‐Ussing
Ole Thorlacius‐Ussing
SLSøren Laurberg
Søren Laurberg
Compromised immune function may increase the risk of anal squamous cell carcinoma (SCC). We examined the risk of anal SCC in patients with HIV infection and other chronic disorders associated with immunosuppression. A population‐based cohort study was conducted using the Danish National Patient Registry and the Danish Cancer Registry (DCR). We identified all patients with a first‐time hospital contact or procedure for HIV infection, solid organ transplantation or autoimmune disease or a first‐time record of haematologic malignancy in the DCR, 1978–2005, and followed these for a subsequent anal SCC, starting follow‐up 1 year after diagnosis of the index disease. Standardised incidence ratios (SIRs) were computed as the ratio of observed to expected numbers of anal SCCs, based on national age‐, sex‐ and period‐specific rates. Among 4,488 patients with HIV, we observed 21 anal SCCs with 0.3 expected (SIR: 81.1 (95% confidence interval (CI): 51.6–121.9)). Risk of anal SCC was markedly increased among 5,113 solid organ recipients (SIR: 14.4 (CI: 7.0–26.4)) and 30,165 patients with haematologic malignancies (SIR: 2.3 (CI: 1.1–4.2)) but only moderately increased among 242,114 patients with autoimmune diseases (SIR: 1.3 (CI: 1.0–1.6)). SIRs varied according to type of autoimmune disease and were high in patients with Crohn's disease (SIR: 3.1 (CI: 1.2–6.4)), psoriasis (SIR: 3.1 (CI: 1.8–5.1)), polyarteritis nodosa (SIR: 8.8 (CI: 1.5–29.0)) and Wegener's granulomatosis (SIR: 12.4 (CI: 2.1–40.8)). In conclusion, we found HIV infection, solid organ transplantation, haematologic malignancies and a range of specific autoimmune diseases strongly associated with increased risk of anal SCC.

10 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
HKHenrik B. Bygum Krarup
Henrik B. Bygum Krarup
KSKåre Gotschalck Sunesen
Kåre Gotschalck Sunesen
MJMartin Johansen
Martin Johansen
MSMogens Tornby Stender
Mogens Tornby Stender
OTOle Thorlacius-Ussing
Ole Thorlacius-Ussing
Colorectal cancer (CRC) is one of the most common cancers in the western world. Screening is an efficient method of reducing cancer-related mortality. Molecular biomarkers for cancer in general and CRC in particular have been proposed, and hypermethylated DNA from stool or blood samples are already implemented as biomarkers for CRC screening. We aimed to evaluate the performance of proven hypermethylated DNA promoter regions as plasma based biomarkers for CRC detection. We conducted a cross-sectional case-control study of 193 CRC patients and 102 colonoscopy-verified healthy controls. Using methylation specific polymerase chain reaction, we evaluated 30 DNA promoter regions previously found to be CRC specific. We used multivariable logistic regression with stepwise backwards selection, and subsequent leave-pair-out cross validation, to calculate the optimism corrected area under the receiver operating characteristics curve (AUC) for all stage as well as early stage CRC. None of the individual DNA promoter regions provided an overall sensitivity above 30% at a reasonable specificity. However, seven hypermethylated promoter regions (ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, and VIM) along with the covariates sex and age yielded an optimism corrected AUC of 0.86 for all stage CRC and 0.85 for early stage CRC. Overall sensitivity for CRC detection was 90.7% at 72.5% specificity using a cut point value of 0.5. Individual hypermethylated DNA promoter regions have limited value as CRC screening markers. However, a panel of seven hypermethylated promoter regions show great promise as a model for CRC detection.

8 June 2016 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
SRSimon Ladefoged Rasmussen
Simon Ladefoged Rasmussen
HKHenrik Bygum Krarup
Henrik Bygum Krarup
KSKåre Gotschalck Sunesen
Kåre Gotschalck Sunesen
IPInge Søkilde Pedersen
Inge Søkilde Pedersen
PMPoul Henning Madsen
Poul Henning Madsen
OTOle Thorlacius‐Ussing
Ole Thorlacius‐Ussing